XenoSTART is proud to sponsor the Tumor Models London Conference, taking place December 4-5. This event is an incredible opportunity for the oncology research community to connect, share knowledge, and advance cancer research. ? At XenoSTART, we’re committed to supporting groundbreaking preclinical research. Our growing PDX inventory of 2,500+ models provides researchers with valuable tools to better understand and combat cancer. And best of all, our models are sourced directly from our patients across our Phase 1 clinics. ? Are you looking to enhance your preclinical studies? Let’s discuss how our models can support your R&D goals. Schedule a meeting: https://lnkd.in/eDrWxzRn ? #TumorModelsLondon #CancerResearch #PDXModels #PreclinicalResearch Lindsay Belcher, Ryan Carpentier, Alyssa Simonson, Dr. Michael Wick, Ph.D.
关于我们
XenoSTART is an industry-leading oncology translational research organization focused on the development and utilization of PDX models. Founded in 2007, XenoSTART was created in close collaboration with?The START Center, an international cancer treatment and research organization.?This partnership provides the?unique ability?to generate clinically-relevant XenoSTART patient-derived xenograft (XPDX) models.? Our diverse repository of XPDX (XenoSTART PDX)?models are clinically annotated and include?patient treatment history and outcome. The models are characterized through genomic profiling, histologic analysis, next generation sequencing, and in vivo drug sensitivity to relevant standards of care. Our models can accelerate preclinical discovery and drug development through the following turn-key services: In vivo PK/PD and efficacy studies In-licensing of models for proprietary studies Orthotopic and radiotherapy studies [collaboration with our partners] Ex vivo and organoid studies [collaboration with our partners] In vivo efficacy panel screens [indication or target focused] Cell line development Custom model development
- 网站
-
https://portal.xenostart.com/login
XenoSTART的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- San Antonio，TX
- 类型
- 私人持股
地点
-
主要
获取路线
US，TX，San Antonio，78229
XenoSTART员工
动态
-
In preclinical cancer research, not all PDX models are created equal. XenoSTART is redefining research integrity with PDX models that are clinically sourced and rigorously annotated to reflect real-world clinical conditions and minimize research risks. Here’s what sets XenoSTART’s PDX models apart: they’re sourced directly from our global START clinics and partner practices, ensuring authentic patient-derived models that capture the true complexities of clinical disease. With superior, deeply annotated data, our models provide actionable insights that help you avoid delays and drive impactful results. See for yourself. Explore our PDX models today in our Catalog and take the first step toward enhancing your research: https://lnkd.in/eRciHcYn #PDXmodels #PreclinicalResearch #OncologyResearch